• Cerenome entered a senior secured financing agreement with 3i Fund for a facility of up to USD 20 million.
• Initial tranche funded at closing; additional tranches become available upon achievement of specified milestones.
• Repayments are structured as royalties, aiming to limit shareholder dilution.
• Proceeds target commercial scale-up of the CNSide cerebrospinal fluid assay platform.
• Cash runway forecast extends into 2028, factoring in the 3i facility, existing facilities, cash, sales, cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100715PRIMZONEFULLFEED9824299) on September 10, 2026, and is solely responsible for the information contained therein.